Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitis.

Fiche publication

Date publication

février 2024

Journal

International journal of cosmetic science

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GALZI Jean-Luc

Tous les auteurs :
Frossard N, Coïc A, Saguet T, Coïc A, Himbert F, Do QT, Galzi JL, Suehs C, Guillaumet G, Bonnet P, Bernard P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38326978

Résumé

Atopic dermatitis has a marked economic impact and affects the quality of life. A cosmetic compound with an innovative strategy is proposed here as a small chemical neutraligand, GPN279 (previously identified as a theophylline derivative), that binds and potently neutralizes the TARC/CCL17 chemokine, activating the Th2 cell-expressed CCR4 receptor.